Flag of the European Union EU Clinical Trials Register Help

Clinical trials for 1

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    39,320 result(s) found for: 1. Displaying page 690 of 1,966.
    «« First « Previous 686  687  688  689  690  691  692  693  694  Next» Last»»
    EudraCT Number: 2020-003326-23 Sponsor Protocol Number: DT-DP-DFU-CR-05 Start Date*: 2021-07-05
    Sponsor Name:DermaTools Biotech GmbH
    Full Title: A Prospective, Randomized, Double-Blind, Vehicle-Controlled Study To Evaluate The Safety and Efficacy of Diperoxochloric Acid (DPOCl, DermaPro®) In Patients With Non-Healing Diabetic Foot Ulcers
    Medical condition: 3. Diabetic foot ulcer treated unsuccessfully for at least 4 weeks with mean diameter between 1.5 and 4 cm after débridement
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001129-17 Sponsor Protocol Number: LDLL300.301 Start Date*: 2017-06-19
    Sponsor Name:AOP Orphan Pharmaceuticals GmbH
    Full Title: A multicenter, open-label study to investigate the effectiveness and safety of AOP Landiolol in controlling supraventricular tachycardia in pediatric patients (LANDI-PED).
    Medical condition: Supraventricular tachycardia in pediatric patients.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    20.0 10007541 - Cardiac disorders 10074640 Junctional ectopic tachycardia PT
    20.0 10007541 - Cardiac disorders 10042604 Supraventricular tachycardia PT
    20.0 10007541 - Cardiac disorders 10003662 Atrial flutter PT
    20.0 10007541 - Cardiac disorders 10040752 Sinus tachycardia PT
    20.0 10007541 - Cardiac disorders 10003668 Atrial tachycardia PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) DE (Ongoing) LT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-000963-22 Sponsor Protocol Number: VTX-801_CLN_001 Start Date*: 2021-10-18
    Sponsor Name:Vivet Therapeutics SAS
    Full Title: A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients with Wilson’s Disease
    Medical condition: Wilson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10047988 Wilson's disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004394-49 Sponsor Protocol Number: LIB003-007 Start Date*: 2021-08-12
    Sponsor Name:LIB Therapeutics, LLC
    Full Title: Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at ...
    Medical condition: Patients With Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at High Risk for Cardiovascular Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    20.0 100000004850 10057080 Homozygous familial hypercholesterolemia LLT
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004203-41 Sponsor Protocol Number: 54767414MMY2040 Start Date*: 2018-04-26
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-004914-79 Sponsor Protocol Number: CA017-003 Start Date*: 2016-10-22
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
    Medical condition: Advanced Malignant Tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Completed) NO (Completed) FI (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-003176-16 Sponsor Protocol Number: ADP-0055-003/GOG-3084 Start Date*: 2023-07-03
    Sponsor Name:Adaptimmune LLC
    Full Title: A PHASE 2, OPEN-LABEL, RANDOMIZED, NON-COMPARATIVE CLINICAL TRIAL OF ADP-A2M4CD8 MONOTHERAPY AND IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH RECURRENT OVARIAN CANCERS (SURPASS-3 STUDY/ GOG-3084)
    Medical condition: Recurrent ovarian cancer positive for MAGE-A4 in human leukocyte antigen (HLA)-A2+ subjects
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000715-31 Sponsor Protocol Number: ACTIV-4 Start Date*: 2022-08-24
    Sponsor Name:NEAT ID
    Full Title: Clinical Trials targeting macro-, micro-immuno-thrombosis, vascular hyperinflammation, and hypercoagulability and renin-angiotensin-aldosterone system (RAAS) in hospitalized patients with COVID-19 ...
    Medical condition: COVID-19 viral infection
    Disease: Version SOC Term Classification Code Term Level
    24.1 100000004862 10085775 Laboratory confirmed COVID-19 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000105-73 Sponsor Protocol Number: OPTIMAL Start Date*: 2019-05-22
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Efficacy of metfOrmin in PrevenTIng glucocorticoid-induced diabetes in Melanoma, breAst or Lung cancer patients with brain metastases: the phase II OPTIMAL study
    Medical condition: Patients with melanoma, lung or breast cancer with encephalic metastases.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049790 Lung neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005875-10 Sponsor Protocol Number: VGFTe-ROP-2036 Start Date*: 2022-03-10
    Sponsor Name:Regeneron Pharmaceuticals. Inc.
    Full Title: An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study
    Medical condition: Retinopathy of prematurity (ROP)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10038933 Retinopathy of prematurity PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001292-14 Sponsor Protocol Number: CV029-009 Start Date*: 2022-11-30
    Sponsor Name:MyoKardia, Inc.
    Full Title: A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants with Symptomatic Hypertrophic Cardiomyopathy and Le...
    Medical condition: Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-006114-20 Sponsor Protocol Number: AML2420 Start Date*: 2021-09-28
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: A Phase 2, prospective, multi-center intervention trial in patients with acute myeloid leukemia secondary to myeloproliferative neoplasms unfit for intensive chemotherapy investigating a treatment ...
    Medical condition: Acute Myeloid Leukemia secondary to myeloproliferative neoplasms
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060355 Acute myeloid leukaemia in remission LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000064-21 Sponsor Protocol Number: TPN-101-AGS-201 Start Date*: 2022-09-20
    Sponsor Name:Transposon Therapeutics Inc
    Full Title: A Phase 2a Study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS)
    Medical condition: Aicardi-Goutières Syndrome (AGS)
    Disease: Version SOC Term Classification Code Term Level
    22.1 10010331 - Congenital, familial and genetic disorders 10083189 Aicardi-Goutieres syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000662-18 Sponsor Protocol Number: CORT125134-556 Start Date*: 2023-02-27
    Sponsor Name:CORCEPT THERAPEUTICS
    Full Title: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian...
    Medical condition: Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004589-21 Sponsor Protocol Number: CLNP023B12301 Start Date*: 2021-06-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy
    Medical condition: complement 3 glomerulopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10077827 C3 glomerulopathy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) FR (Trial now transitioned) GR (Trial now transitioned) BE (Completed) CZ (Completed) ES (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003907-16 Sponsor Protocol Number: SPIMD-301 Start Date*: 2022-03-02
    Sponsor Name:Stealth BioTherapeutics Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondr...
    Medical condition: Primary Mitochondrial Disease Resulting from Pathogenic Nuclear DNA Mutations (nPMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    20.0 10010331 - Congenital, familial and genetic disorders 10052635 Cytoplasmic disorders congenital HLGT
    20.0 10010331 - Congenital, familial and genetic disorders 10052637 Genetic mitochondrial abnormalities NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NO (Completed) ES (Completed) IT (Completed) NL (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002447-22 Sponsor Protocol Number: C4671031 Start Date*: 2022-11-21
    Sponsor Name:Pfizer Inc.
    Full Title: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, DOUBLE BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED NIRMATRELVIR/RITONAVIR COMPARED WITH PLACEBO/RITONAVIR FOR THE TREATMENT OF SEVERE COVID...
    Medical condition: SARS-CoV-2 Infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006180-36 Sponsor Protocol Number: 22071-24071 Start Date*: 2011-01-18
    Sponsor Name:EORTC - European Organisation for Research and Treatment of Cancer
    Full Title: Randomized Phase III trial on postoperative chemoradiation in combination with anti EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinomas (HNSCC) with high ris...
    Medical condition: head and neck squamous cell carcinomas (HNSCC) with high risk of locoregional recurrence
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067821 Head and neck cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) SI (Completed)
    Trial results: View results
    EudraCT Number: 2019-001227-12 Sponsor Protocol Number: M19-850 Start Date*: 2020-03-13
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3b, open label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who successfully completed treatment in the M16-046 study
    Medical condition: Moderate to severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FI (Completed) HU (Completed) CZ (Completed) ES (Ongoing) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) HR (Completed) IT (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2021-001634-18 Sponsor Protocol Number: M602011072 Start Date*: Information not available in EudraCT
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lo...
    Medical condition: Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    21.1 100000004852 10024132 Leg spasticity LLT
    20.1 100000004850 10021740 Infantile cerebral palsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) LV (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 686  687  688  689  690  691  692  693  694  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 10 14:20:23 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA